BAUSCH Health

2018

Register for email alerts.

All Categories

Archive

Date 12/19/18

Title

Bausch Health To Reduce Debt By Additional $76 Million, Bringing Total Debt Repayment In Quarter To Approximately $400 Million

Download PDF

Date 12/12/18

Title

Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.

Download PDF

Date 12/05/18

Title

Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses

Download PDF

Date 11/30/18

Title

Bausch Health Announces Redemption Of $200 Million Aggregate Principal Amount Of Its Outstanding 5.625% Senior Notes Due 2021

Download PDF

Date 11/27/18

Title

Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021

Download PDF

Date 11/21/18

Title

Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021

Download PDF

Date 11/19/18

Title

Bausch Health Announces Participation In Upcoming Investor Conferences

Download PDF

Date 11/15/18

Title

Bausch + Lomb Reports More Than Five Million Units Of Contact Lens Materials Recycled By Second Anniversary Of ONE By ONE Recycling Program

Download PDF

Date 11/13/18

Title

Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland

Download PDF

Date 11/07/18

Title

Bausch Health Commences Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021

Download PDF

Date 11/07/18

Title

Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement

Download PDF

Date 11/07/18

Title

Bausch Health To Participate At The Stifel 2018 Healthcare Conference

Download PDF

Date 11/07/18

Title

Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults

Download PDF

Date 11/06/18

Title

Bausch Health Companies Inc. Announces Third-Quarter 2018 Results

Download PDF

Date 10/30/18

Title

Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States

Download PDF

Date 10/30/18

Title

Dr. Andrew C. Von Eschenbach Joins Bausch Health Board Of Directors

Download PDF

Date 10/29/18

Title

Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

Download PDF

Date 10/24/18

Title

Bausch + Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite™ Vision Enhancement System On IBM Cloud

Download PDF

Date 10/23/18

Title

Bausch Health Announces Endowment With The University Of Missouri To Support Student Scholarships

Download PDF

Date 10/15/18

Title

Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference

Download PDF

Date 10/12/18

Title

Bausch Health Companies Inc. Will Release Third-Quarter 2018 Financial Results On November 6

Download PDF

Date 10/11/18

Title

Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology

Download PDF

Date 10/08/18

Title

Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting

Download PDF

Date 10/08/18

Title

Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults

Download PDF

Date 10/02/18

Title

Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali™* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology

Download PDF

Date 09/28/18

Title

Salix Resolves Legacy SEC Investigation With No Penalty

Download PDF

Date 09/27/18

Title

Bausch Health Releases First Annual Corporate Social Responsibility Report

Download PDF

Date 09/27/18

Title

Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

Download PDF

Date 09/26/18

Title

Bausch Health Announces Redemption Of $125 Million Aggregate Principal Amount Of Its Outstanding 7.50% Senior Notes Due 2021

Download PDF

Date 09/24/18

Title

Bausch Health Announces Participation In Upcoming Investor Conferences

Download PDF

Date 09/12/18

Title

Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation

Download PDF

Date 09/11/18

Title

Bausch Health Reduces Debt By Additional $107 Million, Eliminating All Remaining Mandatory Amortization For 2018

Download PDF

Date 09/11/18

Title

Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies

Download PDF

Date 09/10/18

Title

LUMIFY™ Redness Reliever Eye Drops Honored By The National Association of Chain Drug Stores As Product Showcase Winner

Download PDF

Date 09/06/18

Title

Bausch Health Companies To Participate At The Morgan Stanley Global Healthcare Conference

Download PDF

Date 09/05/18

Title

Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery

Download PDF

Date 09/04/18

Title

US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference

Download PDF

Date 08/29/18

Title

FDA Accepts Resubmission Of New Drug Application For Duobrii™1 (Halobetasol Propionate And Tazarotene) Lotion

Download PDF

Date 08/24/18

Title

Ortho Dermatologics Receives FDA Approval For ALTRENO™ (tretinoin 0.05%) Lotion For Acne

Download PDF

Date 08/15/18

Title

Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII™ (halobetasol propionate and tazarotene) Lotion

Download PDF

Date 08/08/18

Title

Ortho Dermatologics Announces 2018 Aspire Higher Scholarship Recipients

Download PDF

Date 08/07/18

Title

Bausch Health Companies Inc. Announces Second-Quarter 2018 Results

Download PDF

Date 08/06/18

Title

US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets

Download PDF

Date 08/03/18

Title

Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

Download PDF

Date 07/18/18

Title

Bausch Health Companies Will Release Second-Quarter 2018 Financial Results On August 7

Download PDF

Date 07/16/18

Title

Bausch Health Companies Inc. Begins Trading Today as "BHC" on NYSE and TSX

Download PDF

Date 07/13/18

Title

Bausch Health Companies Inc. completes name change

Download PDF

Date 07/09/18

Title

Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%

Download PDF

Date 06/26/18

Title

Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)

Download PDF

Date 06/18/18

Title

FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion

Download PDF

Date 06/14/18

Title

Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops

Download PDF

Date 06/12/18

Title

Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins

Download PDF

Date 06/01/18

Title

Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes

Download PDF

Date 05/31/18

Title

Salix To Highlight New Clinical Data During Digestive Disease Week

Download PDF

Date 05/17/18

Title

Valeant Announces Pricing Of Private Offering Of Notes

Download PDF

Date 05/17/18

Title

Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans

Download PDF

Date 05/15/18

Title

Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference

Download PDF

Date 05/10/18

Title

Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference

Download PDF

Date 05/10/18

Title

Valeant To Seek Refinancing of its Existing Credit Agreement

Download PDF

Date 05/08/18

Title

Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance

Download PDF

Date 05/08/18

Title

Valeant Will Become Bausch Health Companies Inc.

Download PDF

Date 05/07/18

Title

Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine

Download PDF

Date 05/07/18

Title

Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies

Download PDF

Date 05/03/18

Title

Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference

Download PDF

Date 05/02/18

Title

Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection

Download PDF

Date 05/02/18

Title

Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication

Download PDF

Date 05/01/18

Title

Valeant announces 2018 Annual Meeting Results

Download PDF

Date 04/27/18

Title

Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting

Download PDF

Date 04/19/18

Title

Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE By ONE Program

Download PDF

Date 04/12/18

Title

Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020

Download PDF

Date 04/12/18

Title

Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration

Download PDF

Date 04/11/18

Title

Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery

Download PDF

Date 04/10/18

Title

Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes

Download PDF

Date 04/09/18

Title

Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology

Download PDF

Date 04/06/18

Title

Valeant Will Release First-Quarter 2018 Financial Results On May 8

Download PDF

Date 04/03/18

Title

Salix Launches 'Let's Talk 2' IBS Awareness Campaign

Download PDF

Date 03/26/18

Title

Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes

Download PDF

Date 03/12/18

Title

Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount

Download PDF

Date 03/12/18

Title

Valeant Announces Pricing of Private Offering of Senior Notes

Download PDF

Date 03/12/18

Title

Valeant Announces Launch Of Private Offering Of Senior Notes

Download PDF

Date 03/12/18

Title

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount

Download PDF

Date 03/08/18

Title

Valeant To Participate At The 2018 Barclays Global Healthcare Conference

Download PDF

Date 02/28/18

Title

Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance

Download PDF

Date 02/28/18

Title

Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020

Download PDF

Date 02/27/18

Title

Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis

Download PDF

Date 02/16/18

Title

Ortho Dermatologics Presents An Analysis Of SILIQ™ (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis

Download PDF

Date 02/14/18

Title

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment

Download PDF

Date 02/09/18

Title

Salix provides update on FDA submission for PLENVU®*

Download PDF

Date 02/09/18

Title

Salix provides update on FDA submission for PLENVU®*

Download PDF

Date 02/06/18

Title

Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28

Download PDF

Date 01/25/18

Title

Valeant Will Reduce Debt By An Additional $200 Million

Download PDF

Date 01/12/18

Title

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

Download PDF

Date 01/09/18

Title

Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference

Download PDF

Date 01/08/18

Title

Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System

Download PDF

Date 01/03/18

Title

Valeant Pays Down $300 Million Of Senior Secured Term Loans

Download PDF

Date 01/03/18

Title

Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference

Download PDF

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE